Valuation: PTC Therapeutics, Inc.

Market Cap 5.3B 4.81B 4.45B 4.01B 7.56B 500B 7.83B 53.41B 21.18B 267B 19.91B 19.48B 848B P/E 2026 *
95.3x
P/E 2027 * 23x
Enterprise Value 3.52B 3.19B 2.95B 2.66B 5.01B 331B 5.19B 35.39B 14.03B 177B 13.19B 12.91B 562B EV / Sales 2026 *
2.66x
EV / Sales 2027 * 2.25x
Free-Float
92.7%
Yield 2026 *
-
Yield 2027 * -
1 day+0.21%
1 week-2.98%
Current month+5.87%
1 month+5.96%
3 months-11.78%
6 months-13.57%
Current year-16.42%
1 week 62.51
Extreme 62.51
66.9
1 month 58.98
Extreme 58.98
70.11
Current year 58.8
Extreme 58.8
90.87
1 year 58.8
Extreme 58.8
90.87
3 years 19.74
Extreme 19.745
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 8.12
Extreme 8.12
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Other

Chairman

0 0.0000%
14/10/26
Section Six Partners
SellCompany -2,500 0.0030%
9/10/26 Exercice

General Counsel

576 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-2.98%-15.29%+242.63% 5.3B
+1.26%+6.61%+41.12%+135.59% 1,286B
+0.79%+3.45%+46.35%+93.56% 688B
+0.20%+1.28%+27.01%+112.80% 521B
-0.44%+3.69%+39.60%+69.51% 386B
+0.55%+0.70%+59.00%+44.20% 364B
-0.12%+0.74%+26.78%+58.43% 302B
+0.37%+0.37%+3.62%+36.44% 287B
-0.30%+1.14%+38.59%+74.61% 252B
+0.08%+0.71%+34.25%+124.32% 208B
Average +0.26%+1.57%+30.10%+99.21% 430B
Weighted average by Cap. +0.54%+3.25%+37.57%+96.41%

Financials

2026 *2027 *
Net sales 1.32B 1.2B 1.11B 998M 1.88B 124B 1.95B 13.29B 5.27B 66.47B 4.95B 4.85B 211B 1.43B 1.3B 1.2B 1.08B 2.04B 135B 2.11B 14.39B 5.71B 71.98B 5.36B 5.25B 228B
Net income 57.12M 51.76M 47.88M 43.2M 81.41M 5.39B 84.28M 575M 228M 2.88B 214M 210M 9.13B 243M 220M 203M 183M 346M 22.88B 358M 2.44B 969M 12.22B 910M 891M 38.79B
Net Debt -1.79B -1.62B -1.5B -1.35B -2.55B -169B -2.64B -18.01B -7.14B -90.1B -6.71B -6.57B -286B -2.08B -1.89B -1.75B -1.57B -2.97B -196B -3.07B -20.96B -8.31B -105B -7.81B -7.65B -333B
Projected Income Statement - Annual - PTC Therapeutics, Inc.
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Employees
991
Date Price Change Volume
13/11/26 US$63.49 +0.21% 502,868
12/11/26 US$63.36 -2.39% 538,718
11/11/26 US$64.91 +1.20% 724,937
10/11/26 US$64.14 -1.37% 630,008
09/11/26 US$65.03 -0.63% 843,279
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - PTC Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
63.49USD
Average target price
100.47USD
Spread / Average Target
+58.24%
  1. Stock Market
  2. Stocks
  3. PTCT Stock